Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

By sjmartinez • November 23, 2023

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 2023 Nov 11;186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub ahead of print. PMID: 37992595.

Tags: durvalumab, health-related quality of life, Hematology/Oncology, Metastatic non-small-cell lung cancer, patient-reported outcomes, POSEIDON, Publications, tremelimumab

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]

B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman

Cai J, Sin D, Varda M, Lewis L, Yeh J. B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman. Clin Case Rep. 2026[...]

Putting the Patient at the Center of Patient-Centered Care

Rocque G, Nipp R, Sedrak MS. Putting the Patient at the Center of Patient-Centered Care. JCO Oncol Pract. 2026 Oct 16:OP2600798. doi: 10.1200/OP-26-00798. Epub ahead[...]